Summarized by Masters of Longevity from PR Newswire.
A news article summarizing published Phase 3 study results for a growth therapy in children with hypochondroplasia, outlining study design, measures evaluated, and clinical implications.
Key Takeaways
- Vosoritide treatment increased annualized growth velocity by an LS mean difference of 2.33 cm/year versus placebo.
- Standing height, height Z-score, and arm span all improved significantly versus placebo after 52 weeks.
- Safety profile matched prior achondroplasia studies with mostly mild adverse events and no treatment-related serious events.
